A term sheet was signed with TME Pharma for a joint venture on the GLORIA clinical trial of NOX-A12. A wholly owned subsidiary of TMS Co., Ltd. will be established in Q4 2026 with capital of 50 million yen. Discussions will continue on external financing; whether a license agreement is executed will depend on certain conditions.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4891","jir_company_name":"TMS Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-10-29","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4891-20261029-01.pdf","jir_short_summary":"A term sheet was signed with TME Pharma for a joint venture on the GLORIA clinical trial of NOX-A12. A wholly owned subsidiary of TMS Co., Ltd. will be established in Q4 2026 with capital of 50 million yen. Discussions will continue on external financing; whether a license agreement is executed will depend on certain conditions.","jir_summary":"### Overview of the Business Partnership\nTMS Co., Ltd. has signed a term sheet granting it exclusive negotiation rights to carry out the GLORIA clinical trial for newly diagnosed glioblastoma using NOX-A12 as a joint venture with TME Pharma A.G. The plan is to establish a new company to promote the joint venture; specific terms of any license agreement will be determined through future discussions and based on the status of fundraising.\n\n### Establishment of the New Company and Future Schedule\nThe new company will be 100% funded by TMS Co., Ltd. and is planned to be established in Q4 2026. Capital at the time of establishment will be 50 million yen. The company name, location, and representative at establishment are TBD. After signing the term sheet, whether a license agreement will be executed will be decided taking into account the ability to secure external funding and other factors.","jir_financial_highlights":"Capital at time of new company establishment: 50 million yen (Unknown)\nConsideration for exclusive negotiation rights: Up to 300,000 euros (Unknown)","jir_category":"","jir_hashtags":"#TMSCoLtd, #NOX-A12, #GLORIA, #JointVenture","jir_key_figures":"Capital at time of new company establishment: 50 million yen\nConsideration for exclusive negotiation rights: Up to 300,000 euros\nPlanned timing for new company establishment: Q4 2026","jir_meta_title":"TMS Co., Ltd.: Term Sheet Signed for NOX-A12 Joint Venture and Planned Establishment of Subsidiary\uff5cOctober 2026","jir_meta_description":"TMS Co., Ltd. has obtained exclusive negotiation rights with TME Pharma to joint-venture the GLORIA GBM clinical trial using NOX-A12. A wholly owned subsidiary will be established with capital of 50 million yen in Q4 2026. Execution of a license agreement will depend on subsequent negotiations and fundraising.","jir_og_title":"TMS Co., Ltd.: Term Sheet Signed for NOX-A12 Joint Venture and Planned Subsidiary Establishment","jir_og_description":"TMS Co., Ltd. signed a term sheet to joint-venture the GLORIA clinical trial of NOX-A12. A wholly owned subsidiary is planned for establishment in Q4 2026 with capital of 50 million yen. Whether a contract is executed will depend on future negotiations and fundraising.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59627,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"corporate_restructuring","footnotes":""},"sector":[],"importance":[],"class_list":["post-136941","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n